科拓生物
(300858)
| 流通市值：27.05亿 | | | 总市值：36.42亿 |
| 流通股本：1.96亿 | | | 总股本：2.63亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 169,505,299.61 | 84,995,927.91 | 365,922,713.74 | 267,389,193.46 |
| 营业收入 | 169,505,299.61 | 84,995,927.91 | 365,922,713.74 | 267,389,193.46 |
| 二、营业总成本 | 147,459,157.12 | 67,836,659.83 | 270,340,701.74 | 187,404,480.84 |
| 营业成本 | 89,686,984.26 | 46,399,189.49 | 177,463,082.09 | 128,245,917.3 |
| 税金及附加 | 2,361,253.47 | 439,250.97 | 5,566,068.35 | 3,132,902.91 |
| 销售费用 | 17,681,127.2 | 6,143,296.03 | 38,318,054.25 | 25,080,702.88 |
| 管理费用 | 19,812,947.99 | 9,771,197.55 | 33,000,839.83 | 21,278,385.14 |
| 研发费用 | 22,217,903.42 | 8,754,138.82 | 35,705,391.15 | 24,545,249.12 |
| 财务费用 | -4,301,059.22 | -3,670,413.03 | -19,712,733.93 | -14,878,676.51 |
| 其中:利息费用 | 91,668.79 | 56,593.28 | 144,434.01 | 144,027.51 |
| 其中:利息收入 | 4,408,979.28 | 3,736,900.28 | 19,871,479.57 | 14,528,534.93 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,227,380.39 | 729,717.79 | 1,619,799.22 | 1,436,693.57 |
| 加:投资收益 | 4,050,747.05 | 2,086,079.6 | 2,180,536.37 | 1,419,474.28 |
| 资产处置收益 | -10,142.31 | - | - | - |
| 资产减值损失(新) | - | - | -261,600.94 | - |
| 信用减值损失(新) | -4,724,676.6 | -4,823,958.06 | -3,050,739.84 | -1,559,518.71 |
| 其他收益 | 3,662,152.64 | 1,870,556.34 | 8,533,438.59 | 7,229,049.97 |
| 四、营业利润 | 27,251,603.66 | 17,021,663.75 | 104,603,445.4 | 88,510,411.73 |
| 加:营业外收入 | 32,713.72 | 31,858.89 | 49,602.56 | 23,012.86 |
| 减:营业外支出 | 30,347.3 | 30,232.26 | 823,088.44 | 37,868.54 |
| 五、利润总额 | 27,253,970.08 | 17,023,290.38 | 103,829,959.52 | 88,495,556.05 |
| 减:所得税费用 | 2,156,986.48 | 2,071,990.64 | 9,310,557.09 | 12,263,558.32 |
| 六、净利润 | 25,096,983.6 | 14,951,299.74 | 94,519,402.43 | 76,231,997.73 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 25,096,983.6 | 14,951,299.74 | 94,519,402.43 | 76,231,997.73 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 25,096,983.6 | 14,951,299.74 | 94,519,402.43 | 76,231,997.73 |
| 扣除非经常损益后的净利润 | 18,681,720.57 | 12,461,830.23 | 85,140,331.87 | 67,077,516.38 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0.06 | 0.36 | 0.29 |
| (二)稀释每股收益 | 0.1 | 0.06 | 0.36 | 0.29 |
| 八、其他综合收益 | -4.84 | -4.64 | -19.81 | -52.57 |
| 归属于母公司股东的其他综合收益 | -4.84 | -4.64 | -19.81 | -52.57 |
| 九、综合收益总额 | 25,096,978.76 | 14,951,295.1 | 94,519,382.62 | 76,231,945.16 |
| 归属于母公司股东的综合收益总额 | 25,096,978.76 | 14,951,295.1 | 94,519,382.62 | 76,231,945.16 |
| 公告日期 | 2026-08-24 | 2026-04-22 | 2026-04-22 | 2025-10-22 |
| 审计意见(境内) | | | 标准无保留意见 | |